IRIS
NOZZA, SILVIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 248
NA - Nord America 237
AS - Asia 62
Totale 547
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 237
SE - Svezia 159
CN - Cina 48
IT - Italia 44
RU - Federazione Russa 17
FI - Finlandia 16
DE - Germania 5
SG - Singapore 5
IE - Irlanda 4
ID - Indonesia 3
IN - India 3
JP - Giappone 2
ES - Italia 1
FR - Francia 1
NL - Olanda 1
PH - Filippine 1
Totale 547
Salva come PNG Salva come JPEG
Città #
Lawrence 51
Princeton 51
New York 48
Shanghai 31
Milan 20
Helsinki 15
Ashburn 14
Busto Arsizio 6
Moscow 5
Dublin 4
Campodolcino 3
Perm 3
Rome 3
Seattle 3
St Petersburg 3
Gatchina 2
Hanover 2
Huskvarna 2
Jakarta 2
Pune 2
Tokyo 2
Vaprio d'Adda 2
Vittoria 2
Voronezh 2
Andover 1
Banda Aceh 1
Bologna 1
Borås 1
Cuneo 1
Falkenstein 1
Forlì 1
Lappeenranta 1
Littleton 1
Madrid 1
Mandaluyong 1
Naaldwijk 1
Nizhniy Novgorod 1
Paris 1
Pescara 1
Sacramento 1
Singapore 1
Stockholm 1
Ternate 1
Washington 1
Totale 298
Salva come PNG Salva come JPEG
Nome #
Failure of on-demand pre-exposure prophylaxis: the risk of HIV drug resistance 28
Viral bloodstream detection in mpox patients: An observational multicentric study 24
Publisher Correction: Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 (Scientific Reports, (2020), 10, 1, (21291), 10.1038/s41598-020-78039-1) 22
Prior Neisseria meningitidis (Nm) proctitis does not prevent Neisseria gonorrhoeae (Ng) proctitis among men who have sex with men (MSM) 18
Dynamics of adaptive and innate immunity inpatients treated during primary human immunodeficiency virus infection: Results from Maraviroc in HIV Acute Infection (MAIN) randomized clinical trial 18
Enhanced immunological recovery with early start of antiretroviral therapy during acute or early HIV infection–results of Italian network of acute HIV infection (Inaction) retrospective study 17
48 week outcomes of maraviroc-containing regimens following the genotypic or Trofile assay in HIV-1 failing subjects: the OSCAR Study 16
Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients 16
Pharmacokinetics of the raltegravir/maraviroc/etravirine combination 14
Activating Killer Immunoglobulin Receptors and HLA-C: A successful combination providing HIV-1 control 14
Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection 14
Beneficial effects of cART initiated during primary and chronic HIV-1 infection on immunoglobulin-expression of memory B-cell subsets 14
Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection-authors' response 13
Estimated glomerular filtration rate trajectories in HIV-infected subjects treated with different ritonavir-boosted protease inhibitors and tenofovir disoproxil fumarate or abacavir 13
A new antigen scanning strategy for monitoring HIV-1 specific T-cell immune responses 13
Characteristics of HIV pre-exposure prophylaxis users at first PrEP counselling visit: the CSL-PrEP cohort 13
Resistance to amprenavir before and after treatment with lopinavir/ritonavir in highly protease inhibitor-experienced HIV patients 12
Antiretroviral therapy in geriatric HIV patients: The GEPPO cohort study 12
An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim Project. 11
B-cell subset alterations and correlated factors in HIV-1 infection 11
Presence of multiple genotypes in subjects with HPV-16 infection is highly associated with anal squamous intraepithelial lesions in HIV-1 infected males 11
The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort 11
Late positivization of oropharyngeal, plasma, anal, semen, and urine specimens which tested negative at the time of mpox diagnosis 10
Durability of a novel salvage therapy in R5 HIV-infected patients: maraviroc, raltegravir, etravirine 10
Ageing with HIV: a multidisciplinary review 9
Complexity and Dynamics of HIV-1 Chemokine Receptor Usage in a Multidrug-Resistant Adolescent 9
Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism 9
Detecting impaired glucose tolerance or type 2 diabetes mellitus by means of an oral glucose tolerance test in HIV-infected patients 9
Residual viremia in HIV-infected patients who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor based regimen 9
Efficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically suppressed HIV-positive patients on stable antiretroviral therapy 8
Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption 8
HIV-1-mediated insertional activation of STAT5B and BACH2 trigger viral reservoir in T regulatory cells 8
Four-year outcome of a PI and NRTI-sparing salvage regimen: maraviroc, raltegravir, etravirine 8
Soluble endothelial protein C receptor (sEPCR) as an inflammatory biomarker in naive HIV-infected patients during ART 8
Maraviroc 150mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN study 8
Meningococcus B Vaccination Effectiveness Against Neisseria gonorrhoeae Infection in People Living With HIV: A Case-Control Study 8
Increasing incidence and prevalence of metabolic syndrome in people living with HIV during the COVID-19 pandemic 7
Viral Hepatitis and Human Papillomavirus Vaccination during HIV Pre-Exposure Prophylaxis: Factors Associated with Missed Vaccination 7
Human Monkeypox Experience in a Tertiary Level Hospital in Milan, Italy, between May and October 2022: Epidemiological Features and Clinical Characteristics 7
Immune recovery and T cell subset analysis during effective treatment with maraviroc 7
Performance of commonly used genotypic assays and comparison with phenotypic assays of HIV-1 coreceptor tropism in acutely HIV-1-infected patients 7
Viral rebound after switch to maraviroc/raltegravir dual therapy in highly experienced and virologically suppressed patients with HIV-1 infection 7
Maraviroc in addition to cART during primary HIV infection: Results from MAIN randomized clinical trial and 96-weeks follow-up 7
Pustulosis acuta generalisata following chemotherapy in an HIV-positive patient 7
Durability and safety of a novel salvage therapy in R5-tropic HIV-infected patients: Maraviroc, raltegravir, etravirine 7
High Propensity to Switch to Long-acting Injectable HIV PrEP with Cabotegravir in a Cohort of Oral PrEP Experienced Men who Have Sex with Men in Italy 6
Mpox Outbreak 2022: A Comparative Analysis of the Characteristics of Individuals Receiving MVA-BN Vaccination and People Diagnosed with Mpox Infection in Milan, Italy 6
HIV viral load monitoring during monkeypox virus infection among people with HIV 6
Two individuals with potential monkeypox virus reinfection 6
Immortal time bias: authors' reply 6
The Less Drugs Regimens (LDRs) therapy approach in HIV-1: an Italian expert panel perspective for the long-term management of HIV-1 infection. 6
Influence of gender in predicting CCR5 coreceptor usage 6
Prevalence and Risk Factors of Anal HPV Infection in MSM Living With HIV: Identifying the Target Groups to Prioritize for Immunization 6
Role of multi-site sampling in the diagnosis of human Monkeypox 5
Mpox in people with past infection or a complete vaccination course: a global case series 5
HIV DNA loads, plasma residual viraemia and risk of virological rebound in heavily treated, virologically suppressed HIV-infected patients. 5
Viral tropism by geno2pheno as a tool for predicting CD4 decrease in HIV-1-infected naive patients with high CD4 counts 5
Etravirine plasma exposure is associated with virological efficacy in treatment-experienced HIV-positive patients 5
Long-term glucose tolerance in highly experienced HIV-infected patients receiving nucleoside analogue-sparing regimens 5
RPV plus DRV/cobi as 2DR option in HIV-infected subjects on virologic suppression 5
Human seminal plasma stimulates the migration of CD11c+ mononuclear phagocytes to the apical side of the colonic epithelium without altering the junctional complexes in an ex vivo human intestinal model 5
Isolated monkeypox proctitis among men who have sex with men 4
Breakthrough monkeypox infection among individuals previously immunized with smallpox or monkeypox vaccination 4
Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience 4
Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA Study Group 4
Levels of soluble endothelial protein C receptor are associated with CD4+ changes in Maraviroc-treated HIV-infected patients. 4
Is statin preventing cancer in HIV-1 infected individuals? An inappropriate methodology is a more likely explanation: authors' reply 4
A case of breakthrough mpox infection in an individual non-responder to MVA-BN vaccination 4
Mpox Virus: Control of In-Hospital Occupational Transmission Experience from a Tertiary Level Hospital in Milan, Italy 3
Rapid improvement of severe Mpox lesions with oral tecovirimat 3
Persistent ocular mpox infection in an immunocompetent individual 3
Persistence of CCR5 usage among primary human immunodeficiency virus isolates of individuals receiving intermittent interleukin-2 3
Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group 3
Use of statins and risk of AIDS-defining and non-AIDS-defining malignancies among HIV-1 infected patients on antiretroviral therapy 3
Totale 653
Salva come PNG Salva come JPEG
Categoria #
all - tutte 10.285
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.285
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204 4 0 0 0 0 0 0 0 0 0 0 0
2020/20217 0 0 0 0 0 0 1 6 0 0 0 0
2021/202238 0 0 0 14 2 2 2 4 0 7 0 7
2022/2023280 114 66 14 2 1 30 12 30 5 2 1 3
2023/2024288 8 10 42 31 38 82 15 31 1 10 20 0
Totale 653